PharVision Advisers’s Mueller Industries MLI Stock Holding History

PharVision Advisers’s Portfolio MLI Stock Details MLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-3,582	Closed	-$206K	–	432
2025 Q4	$206K	Sell	3,582 -1,850	-34%	-$99.5K	0.1%	536
2025 Q3	$275K	Sell	5,432 -2,268	-29%	-$104K	0.15%	280
2025 Q2	$306K	Buy	+7,700	New	+$291K	0.44%	78

Other funds holding MLI

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

PharVision Advisers's MLI Position: Q1 2026 in Review

PharVision Advisers sold out of Mueller Industries (MLI) in Q1 2026, closing a stake of 3,582 shares — an estimated $206K sold.

PharVision Advisers first reported a position in MLI in Q2 2025 and held it in 3 quarters. The position peaked at $306K in Q2 2025. 722 funds tracked by Wall St. Rank hold MLI as of Q1 2026.

PharVision Advisers reported no remaining Mueller Industries position as of Q1 2026 after selling out during the quarter.
PharVision Advisers sold 3,582 Mueller Industries shares in Q1 2026, an estimated $206K.
PharVision Advisers first reported a position in Mueller Industries in Q2 2025 and held it in 3 quarters.
PharVision Advisers's Mueller Industries position peaked at $306K in Q2 2025.
722 funds tracked by Wall St. Rank held Mueller Industries as of Q1 2026.

Based on PharVision Advisers's 13F filing for Q1 2026, filed 22 Apr 2026.